Summary
All extracted claims are about patent status, market exclusivity, generic availability, and investigational/potential indications; none are supported by the provided FDA label sections for SOOLANTRA (ivermectin) cream (rosacea indication).
Category Scores
Accurate Statements
Unsupported Statements
Ivermectin was initially patented in the 1970s by Merck.
Not present in the provided label sections.
Ivermectin's primary uses are now off-patent.
Not present in the provided label sections.
The foundational patents for ivermectin developed by Merck expired decades ago.
Not present in the provided label sections.
Generic versions of ivermectin for its established antiparasitic uses are widely available.
Not present in the provided label sections.
Patents related to ivermectin may exist for novel formulations.
Speculative/policy/legal content not present in the provided label sections.
Patents related to ivermectin may exist for delivery methods.
Speculative/policy/legal content not present in the provided label sections.
Patents related to ivermectin may exist for specific medical uses.
Speculative/policy/legal content not present in the provided label sections.
Subsequent patents on ivermectin can affect market exclusivity for specific innovations.
Not present in the provided label sections.
Companies may challenge existing patents on ivermectin if they believe the patents are invalid.
Not present in the provided label sections.
Companies may challenge ivermectin patents if they intend to bring a generic version of a patented formulation or application to market.
Not present in the provided label sections.
Research into ivermectin's potential efficacy for various medical conditions, including some viral infections, is ongoing.
Not present in the provided label sections.
If new substantiated therapeutic uses of ivermectin are discovered and meet regulatory standards, they could potentially lead to new patent applications for those indications.
Speculative legal/patent consequence content not present in the provided label sections.
Contradictions
Important Omissions
No FDA-label-consistent statements were provided regarding the labeled indication (treatment of inflammatory lesions of rosacea) and related labeled usage/dosing/safety information; the submitted claims are unrelated to the labeling provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The extracted claims are primarily about patent/market/legal and speculative research topics; they do not directly provide dosing, contraindications, warnings, or clinical management instructions from the label. However, lack of label support means the content may be misleading or distract from appropriate labeling-consistent information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All claims are absent from the provided FDA label sections and pertain to legal/market/patent and investigational topics rather than the labeled rosacea use and labeled safety/dosing.
Suggested Improvement
Replace patent/market/legal and speculative research statements with FDA-label-supported content (e.g., indicated use for inflammatory lesions of rosacea; labeled dosing/application instructions; labeled contraindications; labeled warnings/precautions, drug interactions, and safety in indicated populations as available).